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ABSTRACT

Initiating a Practice Change: Prescribing Probiotics
Concurrently with Antibiotic Therapy
Patty Hermosilla

Background and Significance
Over half of all hospitalized patients are treated with
antibiotics and antibiotic use is rising. There has been a 500%
increase in antibiotic associated diarrhea, a common side effect
of antibiotic use, in the last decade. Probiotics are a safe and
cost effective measure to prevent or reduce antibiotic
associated diarrhea.
Problem Statement
The majority of patients admitted to the medical intensive
care unit receive antibiotic therapy; however, few are
prescribed probiotic therapy concurrent with antibiotics.
Project Design
Education was provided to health care providers regarding
antibiotic associated diarrhea and the benefits of probiotic
use. A guideline was developed to assist health care providers
in ordering probiotics.
Evaluation Plan
Health care providers’ knowledge, attitude, and beliefs,
pre and post education intervention were evaluated. Probiotic
prescribing rates were tracked pre and post intervention.
Results
There was a statistically significant increase in knowledge
and a significant change in attitude after the education
intervention. There was also a 2 fold increase in prescribing
rates; however a very small number of probiotics were
prescribed.
Recommendations
Attempt this practice change on a unit with a more stable
staff and a non ICU population. Potentially use yogurt instead
of a probiotic tablet in the practice guideline. Also,
soliciting change champions may promote probiotic use. Using a
flag in the medication ordering system to remind providers to
order a probiotic or yogurt concurrently with antibiotic therapy
may also increase probiotic prescription rates. Additional
research at the institution is recommended to demonstrate the
effectiveness of probiotics.
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Introduction
Antibiotic use for hospitalized patients continues to
increase, as do the complications, costs, and morbidities from
diarrhea associated with antibiotics. Probiotics have been shown
to prevent or reduce the incidence of diarrhea associated with
antibiotics. This project investigated the effect of an
education session and prescription guideline on the knowledge,
attitudes, and beliefs of physicians and nurses regarding
probiotics, as well as on rates of prescribing a probiotic
concurrently with antibiotic therapy pre and post intervention.

Background and Significance
Over half of all hospitalized patients are treated with
antibiotics, which accounts for 20-50% of all hospital drug
costs (Pestotnik, Classen, Evans, & Burke, 1996). Even though
there is concern about bacterial resistance, antibiotic use at
United States hospitals is rising (Dunham, 2008). At a group of
United States academic medical centers, antibiotic use rose 7
percent from 2002 to 2006 (Pakyz, MacDougall, Oinonen, & Polk,
2008). Antibiotic associated diarrhea (AAD) is a frequent side
effect of antibiotic use. In the last decade, there has been a
500% increase in cases of AAD (Meier, 2005).
The clinical presentation of AAD ranges from mild to
severe. Pseudo membranous Clostridium difficile (C. difficile)
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is a toxin-induced colitis and the most severe manifestation of
AAD (Meier, 2005). In up to 70-80% of diarrhea cases, the cause
of the diarrhea is not specific, and in 20% it is due to C.
difficile (Hurley & Nguyen, 2002). In hospitalized patients, AAD
has been associated with increases in mortality, length of stay,
and cost of medical care (Brossard & Surawicz, 2004).
One of the major mechanisms for the development of AAD is
related to an alteration in the intestinal flora. The intestine
is one of the largest bacterial reservoirs in humans (Gill &
Guarner, 2004). The organisms present in the intestine are
delicately balanced to benefit both the organism and the host. A
multitude of factors can disrupt this balance including food,
drugs, general health, and alteration of the types and numbers
of bacteria present (Gill & Guarner). One of the most
significant causes of disturbance of the gastrointestinal flora
is antibiotic therapy (Sellin, 2001). The normal anaerobic gut
microflora metabolizes high-molecular-weight carbohydrates into
absorbable short-chain fatty acids. When the gut microflora is
altered by antibiotics, high-molecular-weight carbohydrates
accumulate in the colon and cause osmotic diarrhea (Reisinger,
Fritzsche, Drause & Drejs, 2005). Antibiotics that can reduce
the number of gut anaerobes are aminopenicillins,
cephalosporins, and clindamycin (Doron, et al., 2008); however,
almost every antibiotic has the potential to cause AAD and C.
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difficile, including the antibiotics used to treat C. difficile
(Hurley & Nguyen, 2002).
Disturbances of the gut microflora also promote the
overgrowth of distinct pathogenic bacteria. About 16-20% of AAD
cases are caused by C. difficile (Chassany, Michaux & Bergmann,
2000, Reisinger et al., 2005, Sellin, 2001). The triggering
event for C. difficile diarrhea is disruption of the normal
colonic microflora, usually caused by a broad-spectrum
antibiotic (Hurley & Nguyeun, 2002). After the disruption of the
colonic microflora, colonization of C. difficile occurs by
ingestion of heat-resistant spores that convert to vegetative
forms in the colon. The effect of an antibiotic on the
intestinal system depends on the antibacterial spectrum and the
concentration in the intestinal lumen (Chassany et al., 2000).
Moreover, antibiotics with the broadest spectrums like
penicillins, cephalosporins, and clindamycin, and those with a
high intraluminal concentration in the intestinal tract lead to
greater changes in the normal flora of the intestines (Chassany
et al.). The more profound the alteration of intestinal flora by
a given antibiotic, the more likely it is to cause AAD (Doron,
Hibberd & Gorbach. 2008). Bile acids, which escape absorption in
the small bowel, are usually deconjugated and dehydroxylated by
bacteria. When the bacterial flora is disturbed, unmetabolized
dehydroxy bile acids, which are potent secretory agents, lead to
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development of secretory diarrhea in the colon (Reisinger et
al., 2005).
Some antibiotics, such as erythromycin, display a molecular
design similar to that of the paracrine peptide motilin, which
induces intestinal motility. Thus, erythromycin may bind to and
stimulate the motilin receptors, stimulating transit in the
intestine, with resulting increase in intestinal contractility
(Sellin, 2001). Clavulanate also stimulates small bowel
motility.
Other contributing risk factors for the development of AAD
are prolonged use of antibacterial therapy, repeated antibiotic
therapy, and the combination of antibiotics. The highest
incidence of AAD in hospitals is in the intensive care unit
(Bergogne-Berezin, 2000). Additional risk factors for AAD
include: patient immune status and age, route of antibiotic
administration, and inpatient/outpatient status (Boyle, RobinsBrowne, & Tang, 2006). It has been proposed that patients less
than six years of age or greater than 65 years of age, with a
past history of AAD, with severe underlying diseases, with
chronic disease of the GI system, immunosuppression, GI surgery,
or who are receiving antibiotics via nasogastric tube have
increased risk of AAD (Bergogne-Berezin).
The rate of C. difficile acquisition is estimated to be 13%
in patients with hospital stays of up to two weeks and 50% in
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those patients with hospital stays longer than four weeks
(Schroeder, 2005), meaning that patients could experience this
complication well after hospital discharge. C. difficile
diarrhea can occur up to eight weeks after discontinuation of
antibiotics (Hurley & Nguyen, 2002). The cost of treating C
difficile infections is $2000-$4000 per hospital stay (Broussard
& Surawics, 2004;Hickson, 2007).
Significance of Probiotics
Probiotics are defined as live microorganisms that, when
administered in adequate amounts, confer a beneficial effect on
the health of the host (FAO/WHO, 2001). Probiotics modulate
mucosal and systemic immunity, as well as improve nutritional
and microbial balance in the intestinal tract (Penner, Fedorak,
& Madsen, 2005). Probiotics are known to: colonize the
intestinal tract, repopulate the gut with nonpathogenic flora,
enhance immune responses, and inhibit or even kill pathogenic
bacteria (Doron, et al., 2008).
Probiotics are lactic acid producing cultures that
stimulate colonization of the human original flora in a
beneficial direction (Cedgard, 1998). A microorganism must
exhibit certain criteria to be a probiotic. It must be of human
origin, safe in nature, unaffected by gastric acid and bile,
adhere to intestinal mucosa, and be able to produce
antimicrobial substances, modulate immune responses, and
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influence human metabolic activities (Hanaway, 2006). Probiotic
dosages are expressed in billions or millions of organisms, for
example 1010 cfu (colony forming units). Probiotics exhibit
strain-specific differences in their resistance to acid and
bile, ability to colonize the gastrointestinal tract, clinical
efficacy, and benefits to the health of the host (Pham, Lemberg
& Day, 2008). Bifidobacteria and lactobacilli are commonly used
as probiotics (Gill & Guarner, 2004). Lactobacillus rhamnosus GG
(LGG) and Saccharomyces boulardii have the most level 1 evidence
to support use in preventing antibiotic associated diarrhea
(Pham, et al.). Probiotics are a safe, cost effective measure to
prevent or reduce AAD (Hickson, et al., 2007).
Safety of Probiotics
The safety of LGG has been evaluated more than any other
probiotic (Snydam, 2008). In the United States, most probiotics
have the status of generally recognized as safe (GRAS),
therefore probiotics are not subject to specific standards
(Vanderhoff & Young, 2008). However, LGG has been rigorously
studied in academic institutions. These studies have validated
the effectiveness of LGG with AAD (Vanderhoff & Young). LGG has
shown to be safely used in many human populations including
pregnant women, premature neonates, the elderly, children with
diarrhea from rotovirus, hospitalized children and adults with
diarrhea, malnourished children, patients with rheumatoid
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arthritis, adults with Crohn’s disease, adults with Helicobacter
pylori infection, and adults with C. difficile diarrhea
(Snydman). There have been rare cases of bacteremia and liver
abscess in patients with short gut syndrome (Snydam). All
probiotics should be used with caution in patients who: are
immune compromised, have short bowel syndrome, central venous
catheters, elderly patients, and those with cardiac valve
disease (Syndam). In the institution where the practice change
was undertaken, patients are considered immune compromised if
they are: receiving chemotherapy for cancer, have bone marrow
suppression, are hemodynamically unstable beyond a few days or
have multiple organ failure, have received an organ transplant,
have a significant history of alcohol abuse or have a white
blood cell count of <4000 or absolute polymorphonuclear
leukocyte <1000 (H. Dedhia, personal communication, April 15,
2009). Since probiotics are viable organisms, it is feasible
that the host could become infected by them.

However historical

data shows that lactobacilli in either food or capsule form are
safe for human use (Reid, 2003).
It is estimated that there are more than 20 billion doses
of probiotics taken in a year and only a few reports of
bacteremia (Reid, 2005). In a retrospective study by Salminen,
et al. (2004), there were 89 cases of lactobacilli bacteremia,
of which 11 might have been related to probiotic LGG use. In 82%
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of these cases, patients had severe or fatal comorbidities. In
Finland, the annual per capita consumption of LGG increased from
1 liter to 6 liters between 1995 and 2000. Researchers in
Finland studied all Lactobacillus blood isolates from 1990-2000
and found that the rate of Lactobacillus bacteremia remained
constant over time (Ouwehand, Saxelin, & Salminen, 2004 &
Salminen, et al.). Even though probiotic use appears to carry a
very low risk, Doron, et al. (2008) recommends that healthcare
providers change gloves and wash hands after handling LGG and
before manipulating vascular catheters.
Probiotic Dose
According to the World Gastroenterology Organization (2008)
and Hickson, et al. (2007), the recommended dose of LGG for
prevention of AAD in adults is 1010-1011 cfu, BID. This dose was
based on evidence from well-designed and properly powered
clinical trials.

Problem Statement
A large majority of patients admitted to the medical
intensive care unit at the selected trauma center receive
antibiotic therapy, with many receiving multiple antibiotics
concurrently, putting them at high risk for AAD. However, few
patients are prescribed probiotic therapy concurrent with the
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antibiotic treatment, an intervention that might significantly
reduce the risk of AAD.

Theoretical Framework
Two theories guided this capstone project, one serving as a
framework for the patient intervention, and the other a
framework for the provider intervention.
Homeostasis Theory
Claude Bernard’s Homeostasis Theory framed the patient
intervention. In the mid 1800’s Bernard described the importance
of the concept of the constant internal environment. Bernard
believed that life is an expression of the physical reality and
the maintenance of life is guaranteed by the constancy of the
fluid matrix or milieux interieur (Bernard. 1927). Cannon coined
the term homeostasis to describe the constancy of the internal
variable and the regulatory integrated mechanisms directed to
preserve it (Cannon, 1929). Homeostasis does not mean the
environment is immobile or stagnate, but rather that conditions
vary, but remain relatively constant (Cannon). Shortly after
birth, humans become colonized with microbes that are dynamic
components of the body (CAST, 2007). Intestinal microbes are
fairly stable through the life span, but can be impacted by
antibiotics (CAST). Homeostasis is about the condition of an
optimal internal environment for cell and tissue function at any
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moment in time. Health occurs when bodily function is able to
provide the appropriate environment (McVicar & Clancy, 1998).
Failure to provide an optimal internal environment will cause
further destabilization, and the integration of physiological
functioning will become impaired. A change in the activities of
one system may have far-reaching consequences for whole body
function (McVicar & Clancy).
The human gastrointestinal tract is home to over 400
microorganisms. Most of this indigenous flora exhibit health
promoting properties, but some can cause disease. Usually there
is a balance between the good and bad bacteria. However, the use
of antibiotics is known to exert a significant influence on the
number and species of microorganism that inhabit the gut (Gill &
Guarner, 2004). Probiotics can help restore the body’s normal
intestinal flora and the internal environment, thereby
maintaining homeostasis and decrease the risk for AAD and C.difficle, as they occur due to a disruption in the homeostasis
of the GI tract.
Change Theory
Lewin’s Change Theory (Lewin, 1997) was used to guide the
practice change. Lewin’s theory consists of three essential
stages:

unfreezing, moving to a new level or changing, and

refreezing. Unfreezing involves a method of making it possible
for health care providers to change their behavior. To
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facilitate unfreezing education was provided to both physicians
and nurses.
When thoughts, perceptions, feelings, and attitudes move to
a new level, a change has occurred. A guideline was provided to
assist physicians in the process of ordering probiotics.
Additionally, the project director participated in daily rounds
for the first two weeks of the project.
Refreezing is establishing the change as a new habit. This
would occur when it becomes the standard of practice to order
probiotics with certain antibiotics. If refreezing does not
occur, the old behavior returns (Schein, 1995). This would mean
that probiotics would not be ordered.
According to Schein (1995), Lewin’s concept of unfreezing
emphasizes the observation that the stability of human behavior
is based on “quasi-stationary equilibria” supported by a large
force field. Lewin assumes that in any situation there are both
driving and restraining forces that influence any change that
may occur. These forces can be positive, influencing one toward
a behavior, or negative, pushing one away from a behavior.
Driving forces are those forces affecting a situation that are
pushing in a particular direction. Driving forces tend to
initiate a change and keep it going. However, restraining forces
are forces acting to restrain or decrease the driving forces
(Schein).
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For this project unfreezing activities included the
education program which contained information regarding
antibiotic associated diarrhea and the benefit of probiotic use.
Additionally an evidence-based guideline was developed. The
education was presented to the physicians who order probiotics
and to the bedside nurse, who could facilitate the ordering of
the probiotic. During the moving phase, the project director
maintained close contact by participating in rounds with the
physicians in the MICU. This allowed for questions to be
answered and encouragement to be given for the practice change.
The evidence-based practice guideline was in place to assist new
residents who rotate through the unit as well as other
physicians. Driving forces included: encouragement from the
project facilitator, pressure from the staff physicians,
reminders from the bedside nurse, and enthusiasm or “buy in”
generated from the educational program. Restraining forces
included health care providers that doubt the benefit of
probiotics and hence do not order them. Theoretically, in the
refreezing phase, physicians in the MICU would be consistently
ordering probiotics for patients receiving antibiotic therapy
and nurses would support this practice. The effectiveness of the
change was monitored by comparing prescribing rates per and post
guideline introduction and education.
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Project Description
Literature Review
In order to identify potential practice protocols, a
thorough literature search was conducted. Data bases searched
included the National Guidelines Clearinghouse, the Cochrane
Library, Pub Med, and CINAHL from 1999 to present. Search terms
were probiotics, antibiotics, adults, and diarrhea in various
combinations. The National Guidelines Clearinghouse yielded one
guideline but it was not specific to probiotics and diarrhea.
The Cochrane Library yielded three hits: two were protocols not
yet developed and one was a review on probiotics for the
prevention of pediatric antibiotic–associated diarrhea. Pub Med
initially yielded 2201 hits, with probiotic as the search term.
Adding diarrhea narrowed the search down to 545, which was
further narrowed to 40 by adding antibiotics and adult. An
exhaustive review was completed on this search and 7 articles
were retrieved for this paper. Through the use of snowballing
the article from the WHO organization was obtained.
Seven articles will be reviewed, three randomized control
trials, one systematic review, and three meta-analyses. All of
the studies address the use of probiotics with AAD and were
published from 2002-2007.
The focus of a study by Cremonini, Di Caro, Nista,
Bartolozzi, Capelli, G. Gasbarrini, et al. (2002) was to perform
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a meta-analysis of published trials on the efficacy of
probiotics in reducing the incidence of AAD. Inclusion criteria
were: only placebo-controlled trials, diarrhea as the primary
end-point, and only studies with a minimum of two week followup. Data regarding diarrhea was based on presence or absence of
diarrhea; results based on differences in the amount of daily
stool were excluded from analysis. Only seven placebo-controlled
trials matched the inclusion criteria. The trials included used
Lactobacillus spp. or Saccharomyces boulardii a single probiotic
species instead of a combination of probiotics. A total number
of 881 patients were studied in the trials, with an age range of
two weeks to elderly. Of the seven trials reviewed, three
identified a decrease in the occurrence of AAD during
administration of Saccharomyces boulardii and four during the
administration of Lactobacillus spp. The results of this study
showed an overall reduction in the risk of AAD during probiotic
administration in the studies considered. It was further noted
that even though data suggests a positive role for probiotics in
AAD, lack of standardization of probiotic preparations may
impact research findings. The author calls for more equivalent
probiotic formulations.
D’Souza, Rajkimar, Cooke and Bulpitt (2002) performed
another meta-analysis to evaluate the efficacy of probiotics in
prevention and treatment of diarrhea associated with the use of
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antibiotics. All randomized, double blind trials that compared
the effects of probiotic therapy and placebo were included. The
percentage of patients without diarrhea in the probiotic and
placebo groups was used as the outcome measure. Nine trials were
included in the final analysis. All trials studied the efficacy
of a probiotic in the prevention of AAD. The studies used
probiotics combined with one or more antibiotics. The numbers of
patients and duration of follow-up varied greatly from study to
study, but the patients’ characteristics were similar in both
treatment and placebo group. The combined odds ratios were
similar between the yeast trials (Saccharomyces boulardii) and
the non yeast trials; both favored active treatment over placebo
in the prevention of AAD. The odds ratio for pooled data from
all nine trials was in favor of probiotics over placebo in the
prevention of AAD 0.37 (0.26 to 0.53; P<0.001). Six studies
showed a significant benefit of probiotic treatment compared
with placebo. This meta-analysis concluded that probiotics may
be useful in preventing AAD, but it provided little support for
treating AAD already in existence. Moreover, it indicated that
probiotics are increasing in availability, have a low cost, and
lack side effects in contrast to the problems associated with
antibiotics.
In a randomized trial, Beniwal, Arena, Thomas, Narla,
Imperiale, Chaudhry, et al. (2003) studied the effectiveness of
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a dietary supplement of yogurt for the prevention of AAD. Two
hundred two hospitalized adult patients receiving oral or
intravenous antibiotics were randomized to receive or not to
receive a dietary yogurt supplement. The yogurt contained 106
cultures of L. acidophilus, L. bulgaricus, and S. thermophilus
combined. The intervention group received yogurt twice daily for
eight days within 12 hours of starting an antibiotic. Within
each block, six subjects were randomized to one of two groups to
ensure a balance in the number of subjects assigned to receive
yogurt or no treatment. Randomization was stratified according
to whether patients were receiving C. difficile treating
antibiotics, metronidazole or vancomycin, or non C. difficile
treating antibiotics. Treatment assignment was not revealed to
the patient until they agreed to enroll in the study. Yogurt
decreased the risk of developing AAD by nearly 50% (p=0.04).
The total number of diarrheal days was 60 in the control group
and 23 in the yogurt group. The incidence of AAD in the control
was 23.7% which is consistent with other reports of frequency of
AAD. The incidence of AAD in the yogurt group was 12.4%.

Based

on the results, the absolute risk reduction implies that nine
patients (95% confidence interval 4.1-132.6) need to be treated
with yogurt to prevent one case of AAD. The study was not
double-blinded due to the nature of the intervention. However,
patient responses were elicited in a standardized fashion by
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certified dieticians, which may have mitigated the effect of the
lack of blinding. Incorporating a treatment arm consisting of
yogurt without active cultures would have strengthened the
study. It is also noted that the results are based on the
combination of specific probiotics; therefore, the results
cannot be applied to single probiotics or other dosages or
combinations. This study demonstrated that during the course of
antibiotic therapy, supplementation with commercially available
yogurt that contains active cultures is a simple, safe, and
cost-effective method of reducing the occurrence and severity of
AAD.
Hawrelak, Whitten, and Myers (2005) performed a systematic
review to determine if co-administration of LGG with antibiotics
reduced the subsequent incidence of AAD. A systematic review was
done on six, placebo controlled trials that compared the effects
of a probiotic and a placebo on AAD. Statistical heterogeneity
of the trials did not allow meta-analysis. The heterogeneity of
the systematic review was found to be due to one study; without
the one study, the trial results were all statistically
homogenous. Four of the six trials found a significant reduction
in the risk of AAD with co-administration of LGG. One of the
trials reduced the number of days with AAD and the final trial
found no benefit. All patients in the four positive trials
received oral antibiotics and were outpatients. The participants
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in the negative study were inpatients and an unspecified number
of patients received IV antibiotics. There were a total of 638
participants, ages two weeks to 93 years. Daily doses of LGG
ranged from 1 x 1010 to 4 x 1010. Duration of treatment days
ranged from 7-14 days. Limitations of this systematic review
include a small number of studies that examined the use of LGG
and AAD. Some of the studies had a small number of participants.
Additionally different antibiotics were used, as well as
different dosages of LGG. LGG is the probiotic to be
administered in this project and most of the studies showed a
decrease in the percentage of subjects with diarrhea: 5% vs 16%,
8% vs 26%, 29% vs 30%, 3% vs 27% and 5% vs 30%.
McFarland (2006) performed a meta-analysis to compare the
efficacy of probiotics for the prevention of AAD and the
treatment of C. difficile disease (CDD) based on published
randomized, controlled clinical trial. Twenty-five randomized
controlled trials, with a sum total of 2,810 patients, provided
data regarding efficacy of probiotics. The types of probiotics
varied from single strains to mixtures of probiotics. Daily
doses ranged from 1 x 107 to 1 x 1011.

Use of a high dose (> =

1010/day) of probiotic was associated with more effectiveness
with AAD. The duration of probiotic treatment also varied from
five days to eight weeks. In this meta-analysis, three types of
probiotics (Saccharomyces boulardii, LGG, and probiotic
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mixtures) significantly reduced the development of AAD. Only
Saccharomyces boulardii showed significant reductions in
recurrences of CDD. Limitations of this study include the
varying types of probiotics and antibiotics, varying doses,
varying age of participants, and variations in sample size.
Although there were limitations, the data synthesis from twentyfive randomized controlled trials showed that probiotics
significantly reduced the relative risk of AAD. From six of the
randomized controlled trials the combined efficacy showed
probiotics have a significant protective effect for CDD.
A randomized, double blind, placebo controlled trial by
Hickson, D’Souza, Muthu, Rogers, Want, Rajdumar, et al. (2007)
studied the efficacy of a probiotic drink containing
lactobacillus for the prevention of diarrhea associated with
antibiotic use and diarrhea caused by C. difficile. One hundred
and thirty five hospitalized patients taking antibiotics were
studied. The treatment group received a probiotic drink
containing L casei imunitass, (1.0 x 108 cfu/ml), S thermophilus
(1.0 x 108 cfu/ml), and L. bulgaricus (1.0 x 107 cfu/ml).

The

placebo group received a sterile milkshake. The treatment group
and placebo group received the drink twice daily during
antibiotic treatment and for one week after the antibiotic was
completed. Twelve percent of the probiotic group developed AAD
compared to 34% in the placebo group. This study concluded that
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consumption of a probiotic drink containing L casei, L
bulgaricus, and S thermophilus can reduce the incidence of AAD.
The study could not establish which bacteria species was
effective. It is possible that the bacteria work
synergistically, or one species may be more effective than
another. As a result, the results cannot be generalized to other
probiotic products.
In the most recent placebo-controlled, double blind study
by Koning, Jonkers, Stobberingh, Mulder, Rombouts, and
Stockbrugger (2007), the effect of a multispecies probiotic on
the composition and metabolic activity of intestinal microbiota
and bowel habits was studied in healthy volunteers taking
amoxicillin. Forty subjects were enrolled in the study, 19 in
the probiotic group and 21 in the placebo group. Volunteers
received 500 mg of amoxicillin twice daily from day 1-7 and were
randomized to receive either 5 grams of a multispecies probiotic
or 5 grams of a placebo twice daily from day 1-14. The probiotic
contained 10 different bacterial species at each 108 cfu/g, the
total does being 109 cfu/g (b. bifidum, B longum, E. faecium, L.
acidophilus, l. paracasei, la. Plantarum, LGG, and l.
salivarius. Congruent with other studies, the intake of a
multispecies probiotic resulted in a decrease in diarrhea-like
bowel movements. During the probiotic period, diarrhea was
reported less frequently in the probiotic group (48%) than in
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the placebo group (79%). The study used healthy adult volunteers
who received the same oral antibiotic and either a multispecies
probiotic or a placebo.
Synthesis
For the purpose of this literature review, three randomized
controls, one systematic review, and three meta-analyses were
examined. In all of the studies reviewed from 2002-2007,
patients receiving a probiotic reported less frequent diarrhea.
Cremonini, et al. (2002) showed an overall reduction in the risk
of AAD during probiotic administration. D’Souza, et al. (2002)
concluded that probiotics may be useful in preventing AAD, but
provided little support for treating AAD. Beniwal, et al. (2003)
showed that during the course of antibiotic therapy,
supplementation with commercially available yogurt that contains
active cultures is a simple, safe, and cost-effective method of
reducing the occurrence and severity of AAD. Additionally,
Hawrelak found that when LGG was administered, there was a
decrease in the percentage of subjects with diarrhea. In
McFarland’s meta-analysis, the data synthesis from twenty-five,
randomized, controlled trials showed that probiotics
significantly reduced the relative risk of AAD.

Hickson, et al.

(2007) and Koning, et al. (2007) also showed a decrease in the
incidence of developing AAD when the patient was given a
probiotic.
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Based on a review of the literature, there is sufficient
evidence to support the practice of administering probiotics
concurrently with antibiotics in high risk patient populations,
after screening for potential contraindications. The proposed
practice change project is supported by evidence found in the
literature.
Congruence of Organizations Strategic Plan
This project supports the mission, values, goals, and
strategic plan of West Virginia University Hospital (WVUH). The
mission of WVUH is to provide a quality healthcare system,
including tertiary services, to the citizens of West Virginia
and the surrounding region (WVUH, 2008). WVUH (2008) values
patient, team, and community. The mission of WVUH is achieved
through strategic planning with a focus on improving the health
status of the local community and the state of West Virginia and
maintaining a strong financial position (WVUH). This project was
designed to

assist in achieving the mission by improving the

health status of the patients in MICU. The use of probiotics can
promote returning of the patients’ intestinal microflora to a
pre-antibiotic state, thus potentially decreasing mortality and
morbidity (Hickson, et al. 2007). Based upon the findings of a
study by Hickson, et al., it is estimated that a decrease in
patient length of stay might also occur.
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Project Objectives
The main objective of the project was to introduce a
guideline for ordering probiotics concurrently with antibiotics.
An additional objective of the project was to increase knowledge
of physicians and nurses regarding incidence and effect of AAD
and the use of probiotics to reduce the risk for and length of
AAD. Another objective was to achieve a 50% increase in
prescribing rates of probiotics for patients receiving
aminopenicillin, cephalosporin, and clindamycin type antibiotics
in the medical intensive care unit at a Midatlantic academic
hospital by July 2009. The probiotic was to be ordered
concurrently with the antibiotic by the ordering physician. An
additional objective was to impact physician and nurse attitudes
about the safety and effectiveness of probiotic use by
presenting an educational program about the benefit of probiotic
use with antibiotics in patient care. The project was completed
during the period of May-July 2009 (Appendix G).

Project Design
Evidenced Based Intervention Plan
A Curriculum for the Role of Probiotics in the Prevention
of Antibiotic Associated Diarrhea was developed (Appendix A).
Additionally, an evidence-based practice guideline for
prescribing probiotics was developed to assist physicians and

Probiotics

24

nurses in ordering probiotics concurrently with identified
antibiotics (Appendix E). A pretest/posttest was developed based
on a review of the literature. The assessment test was reviewed
for clarity and readability by ten nursing faculty at the School
of Nursing prior to administering the test.
The educational program about probiotics and AAD as well as
the guideline for ordering probiotics was presented at a
research rounds to physicians in the MICU. The nurses in the
MICU were educated by through use of a poster presentation. An
informational poster was placed in the break room in MICU 1,
MICU 2, and SICU. Placing posters in all 3 units assured easy
access to the nurses.
Prior to the education, a Probiotic Knowledge, Attitude,
and Belief Assessment pretest was placed in the mailbox of all
nurses in the MICU and SICU (Appendix F). In addition a letter
explaining the project and thanking the nurses for their
participation was placed in each mailbox. The education program
was approved for continuing education credit; thus a contact
hour was given to all nurses who completed the pretest and
posttest. The pretests were collected throughout a 2 week period
and then the posters were placed in each unit. The poster
remained in the units for 6 weeks, with posttests being
collected periodically throughout the 6 weeks. Certificates for
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contact hours were given to all nurses who completed the
posttest.
The pretest/posttest is a quasi-experimental design as it
measures change within groups. Additionally, prescribing rate of
probiotics for six weeks prior to and six weeks post
intervention and for 13 weeks after the project ended were
obtained from a data analyst for the hospital. The number of
patients admitted to the unit, the number of antibiotics
prescribed, and the numbers of c difficile diagnoses were also
collected.
Resources
The resources for the project included the time of the MICU
director, Dr. Dedhia, and other MICU physicians, residents,
bedside nurses, MICU nursing administrators, pharmacists, and
dieticians. The room and equipment that is normally used for
grand rounds was used for the educational program. The budget
included a cost of $37.00 for preparing the posters. Education
for physicians occurred during research rounds, a routine
education time. The nurses’ education did not take nurses
outside of the care setting, as it occurred via poster board
format. Nurse champions were informally identified during the
education process through expressed interest and enthusiasm for
the project. This allowed for promotion of the project during
times when the project director was not on the unit. Probiotics
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are currently covered by insurance, thus there is generally no
cost to the patient receiving them.

The cost of LGG is $0.14

per dose (G. Gill, personal communication, September 22, 2008)
and insurance is billed the minimum charge of $3.26 (G. Gill
personal communication, September 24, 2008).
Evidence of Key Site Support
Harakh V. Dedhia, MD, medical director of the medical
intensive care unit was in support of the project (Appendix B).
Dr. Dedhia is board certified in internal medicine, pulmonary
disease, and critical care medicine, with a special interest in
nutrition. Chris Frenecak, a registered dietitian for MICU, was
also in support of the project (Appendix C). Mary Fanning,
Nursing Administration Director, granted permission to complete
the project in the MICU (Appendix D).

Evaluation
The project was evaluated in two ways. The health care
provider’s knowledge, attitudes, and beliefs toward probiotic
use were evaluated and probiotic use was monitored. A pretest
was given to the health care providers before the education
program and a posttest followed the education program.
Probiotic prescribing rates, MICU admissions, antibiotic
prescribing rates, and C. difficile rates were obtained from the
data analyst for six weeks prior to the education program and
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for six weeks after the intervention, as well as for 13 weeks
after the project ended.
A paired t-test was used to compare knowledge scores from
the pretest and posttest data. Pre and post intervention
prescribing rates were compared to determine if the goal of a
50% increase was met. In addition antibiotic prescribing rates,
MICU admissions, and C. difficile rates were also compared.

Results
Demographics
Seventy-one percent of the 45 participants completing the
pretest were registered nurses, 16% were physicians, 11% were
dieticians and 2% were respiratory therapists. Forty-two
participants completed the posttest: 64% were registered nurses,
18% were physicians and 11% were dietitians.
Average length of time in practice for all health care
providers was 11.7 years. Physicians had an average of 16 years
with a range of 1-35 years of practice. Years of experience for
nurses ranged from 0-33 years, with an average of 9.34 years.
Dietitians had an average of 21 years of experience, with a
range of 12-35 years. One respiratory therapist completed the
testing with 8 years of experience.
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Pretest/Posttest Results
The survey measured knowledge, attitude, and beliefs.

A

change in knowledge from pretest to posttest was measured with a
paired t test by computing total scores for knowledge on 25
items. The paired t test indicated a significant increase in
test scores after education, t (df = 44) = 7.192, p = .000. Mean
knowledge scores increased from 11.1 (SD = 2.68) pretest to 18.2
(SD = 6.22) posttest.
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Table 1: Knowledge Items: Percent Correct Pre and Post Test

________________________
Questions

Pretest %

Posttest %

correct

correct

________________________________________________________________
1. Probiotics have same benefit,

73

85

67

80

3. Probiotics are not of human origin

80

90

4. Probiotics are affected by gastric

37

23

5. Therapeutic dose of LGG

18

86

6. Probiotics with most level 1

13

74

67

79

7

74

10. Highest AAD population

87

100

11. Rate of C. difficile acquisition

24

76

regardless of stain
2. Probiotics have strain-specific
differences

acid and bile

supportive evidence
7. Major risk factor for development
of AAD
9. Increase in AAD in the last decade

in hospitalized patient
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________________________
Questions

Pretest %

Posttest %

correct

correct

80

83

13. One

38

90

14. Two

36

93

15. Three

34

93

16. Are immune compromised,

65

95

17. Are receiving multiple

81

88

18. Have short bowel syndrome,

61

88

19. Have a central venous catheter,

12

78

20. Are elderly,

67

78

21. Have cardiac valve disease.

33

88

72

89

12. True/false all antibiotics cause
AAD
Name

three

antibiotics

classifications
that

reduce

of
gut

anaerobes.

Probiotics should be used with caution
in patients who

antibiotics,

Precaution when handling a probiotic
22. No precaution,
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________________________
Questions

Pretest %

Posttest %

correct

correct

19

7

24. Use sterile gloves,

100

95

25. Change clean gloves and wash

49

85

23. Thoroughly wash hands after
handling,

hands before central catheter
________________________________________________________________
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Some knowledge questions changed substantially from the
pretest to the posttest. Only 18% correctly identified the
therapeutic dose of LGG on the pretest, while 86% were able to
identify the correct dose on the posttest. Similarly, only
4.5 % correctly identified the rise in antibiotic use from 2002
to 2006 on the pretest, whereas 79% answered correctly on the
posttest. In addition, 7% correctly identified the increase in
AAD over the last decade on the pretest, and 74% on the
posttest.

Only 24% were able to identify the incidence of C.

difficile acquisition on the pretest, whereas 76% were able to
identify the incidence on posttest.

Around 30% of participants

were able to name three classifications of antibiotics that
reduced the number of gut anaerobes on the pretest, whereas over
90% were able to name three classifications of antibiotics on
the posttest. Lastly, the greatest knowledge change regarding
caution in probiotic use was identification of caution in
patients who have a central venous catheter. On the pretest 12%
answered this item correctly, and on the posttest 78% answered
correctly.
Attitude change was measured by computing total score for
items indicating the level of agreement/disagreement with
statements about the prevalence and severity of AAD as a health
problem and the usefulness, safety and effectiveness of
probiotic use concurrently with antibiotics. Low scores
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represented the most positive attitude. There was a significant
difference in pre and post scores, t (df=41) = 2.86, p = .007.
Mean attitude scores decreased from 12.3 to 10.6, indicating a
more positive attitude toward the significance of AAD as a
health issue and the potential benefit of probiotic use. After
education, the reported likelihood of prescribing probiotics
together with antibiotics also increased significantly, t (df=
38) = 3.13, p = .003.Mean scores decreased from 2.7 to 2.0.from
pretest to posttest.
Only 19 (42%) participants had prescribed or recommended a
probiotic and 25 (56%) had never prescribed or recommended a
probiotic. Twenty-nine (64%) of participants have known people
who have used probiotics and 16 (36%) did not know of anyone who
used probiotics. Twenty-five (56%) had personally used
probiotics either in food sources or supplements and 20 (44%)
had not used a probiotic.
Themes in the open response items for reservations about
recommending or prescribing probiotics included not being well
informed on probiotic use and not having seen probiotics used in
practice.

Themes identified with the question, “What might

encourage you to prescribe or recommend probiotics?” included:
more evidence of benefits, more education, increased knowledge,
visual reminders, and ease of administration.
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Prescribing Rates
There were 148 patients admitted to MICU service 6 weeks
prior to the education intervention, and of those patients, 96
(66%) were prescribed antibiotics. Of the patients receiving
antibiotics, 2 (2%) received the probiotic LGG. There were 138
patients admitted to MICU service during the 6 week post
education study period and of those, 82 (59%) were prescribed
antibiotics. Of these patients, 4 (5%) were prescribed the
probiotic LGG. There was a 2 fold increase in probiotic
prescribing rates; however there were a very small number of
probiotics prescribed in total. In the time frame post study
period (June 25-August 31), there were an additional 2 patients
prescribed the probiotic LGG. Hospital-wide, there were 106
patients prescribed a probiotic from January 17- September 18,
2009. The overall probiotic prescribing rate was low throughout
the hospital during this time frame. Probiotics received via a
food source such as yogurt could not be determined, as this data
is not tracked through the medical record system.
One of the two patients that received a probiotic before
the education session had a confirmed diagnosis of C. difficile.
Two of the four patients that received a probiotic during the
six week post education intervention study period had a
confirmed diagnosis of C. difficile, and another had diarrhea
identified in the medical record. The two patients that received
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a probiotic during the post study period both had a confirmed
diagnosis of C. difficile. Eleven patients listed under MICU
services had documented C. difficile pre invention and 5
patients had documented C. difficile post intervention.

Discussion
Limitations
The purpose of this project was to initiate a practice
change to increase probiotic use concurrent with antibiotic use
in the MICU. Several issues may have impacted the effect of the
practice change project. First, the project director was not
present in the unit on a daily basis, to serve as a constant
change agent. Even though the residents who were assigned to
this patient population were provided education regarding the
practice change, the residents in the unit change on a monthly
basis. Thus, residents who prescribed antibiotics during the
latter weeks of the post intervention period most likely had not
attended the education intervention session. The staff
physicians were also provided the education session; however the
staff physician rotates weekly, and all staff MD’s do not attend
the research conference at which the education session was
provided. The physician education session could not be conducted
during grand rounds, where staff physician attendance might have
been higher, due to scheduling conflicts.
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Another limitation was the low rate of nurse completion of
the poster education session. Posters were available in multiple
locations, to assure availability to all staff RNs, yet only 30
nurses (25%) completed the pre and post test. Thus, a large
number of RN’s may have been unaware of the proposed practice
change on the unit. In addition, although the nurses on the unit
can suggest and/or remind physician to order a probiotic, they
cannot themselves prescribe a probiotic for a patient.

It was

not possible to collect data on nurse prompting behaviors; thus
the potential impact of these behaviors is not known.
Another limitation that became apparent related to the
different roles of the project director and the physician
providers. The practice change was being proposed by a nurse
practitioner to physicians in the MICU. Physicians may be
reluctant to change practice based on a recommendation from a
nurse practitioner.
In addition, an unexpected event occurred during the
education session that may have impacted physician attitudes and
behaviors related to the prescribing of probiotics. A pharmacist
who attended the physician education session verbalized strong
lack of support for the practice change. It appeared that he may
not have been aware of the literature documenting the positive
effects of probiotic use concurrent with antibiotics, but,
nevertheless, voiced his concerns about the proposed practice
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change. His comments may have negatively influenced the
attitudes and behaviors of the MDs and residents in attendance
at the session.
Finally, it may be that the MICU is not the best unit to
initiate the practice change of prescribing probiotics
concurrently with antibiotics. The MICU patient population may
have a higher prevalence of conditions for which probiotics use
would be contraindicated or cautioned, such as immunocompromise,
cardiac valve disease, and short bowel syndrome.
Conclusions and Recommendations
This project met the identified objectives to increase the
knowledge of MICU physicians and nurses about the significance
of AAD and the benefits of probiotics in reducing patient risk
for this treatment complication, and to increase prescribing
rates for probiotics concurrent with antibiotics in the MICU
patient population. However, the impact on achieving the mission
and strategic plan of the University Hospital was minimal at
best, because the probiotic prescribing rate, while increased,
remained very low.
As a result of this practice change project, several
recommendations can be made for further interventions to promote
the behavior of prescription of probiotics as adjuncts to
antibiotic prescriptions. First, it might be best to attempt
this practice change on a unit with both stable staff and stable
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prescribers. Then, education would be most likely to affect a
change in practice. A second recommendation would be to
implement the practice change on a unit with a non ICU
population, where there would be less contraindications or
cautions for use with the patient population.
An additional recommendation might be to use a yogurt
containing LGG as an option for implementation of the probiotic,
as physicians may be more willing to suggest yogurt for their
patients than to prescribe a tablet that comes from the
pharmacy. Use of yogurt might be perceived as “safer” than
prescription of a formulary probiotic.
An additional recommendation would be to solicit
champions from medicine, nursing, pharmacy, and dietary to
promote the use of probiotics concurrently with antibiotic
therapy. When there are champions in each area, the staff in
those areas are more likely to participate in the practice
change.
The use of a prompt or flag within the medication
ordering system to remind providers to order a probiotic when
ordering an antibiotic would, most likely, have a more
significant impact on physician prescribing behavior. However,
this change would require hospital-wide change in
policy/procedure, and so would be a longer-term intervention.

Probiotics

39

Finally, conducting research at the institution that may
demonstrate the effectiveness of probiotics in preventing and/or
treating diarrhea resulting from antibiotic therapy might
increase credibility of this behavior and result in increased
“buy in” by physicians. It would be possible to continue to
collect data related to C. difficile rates, the cost of diarrhea
and C. difficile in terms of hospitalization, and probiotic
prescription rates. Perhaps as providers recognize more fully
the effect of preventing even one case of C. difficile, they may
be more amenable to taking the additional steps of prescribing a
probiotic along with the antibiotics that are prescribed.
Summary and Implications
The education session did increase both physician and nurse
knowledge of probiotics, and positively impacted their attitudes
toward the use of probiotics in preventing AAD. In addition, the
rate of probiotic prescription increased two-fold in the posteducation period, even though the prescription rate remained
quite low. There were several intervening or hindering
variables, which may have prevented a further change in attitude
toward probiotics and probiotic prescribing rates. Given these
intervening or hindering influences, several recommendations for
future work in this practice change are suggested.
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Attainment of Leadership Goals
This project has contributed to my personal leadership
goals in numerous ways. After coming up with a question, I was
able to perform a literature review and systematically review
research articles on the topic of probiotics and antibiotic
associated diarrhea. I then incorporated two theories to guide
the practice change. The practice change was designed to improve
patient outcomes by applying research. I participated
interprofessionally with physicians and nurses in the MICU to
increase knowledge, change attitudes and beliefs, and increase
prescribing rates of probiotics concurrently with antibiotics. I
developed, implemented, and evaluated a practice change. I hope
to continue to participate in promoting the use of probiotics
concurrently with antibiotic therapy to prevent or decrease AAD
in other areas of health care.
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Appendix A
Curriculum Outline
The Role of Probiotics in the Prevention of Antibiotic
Associated Diarrhea
1. What are probiotics?
2. The history of probiotics
a. Myths
3. Antibiotic associated diarrhea
a. The role of probiotics
b. Literature review
c. Recommendations
d. Safety Issues
4. Practice Change
a. When to order probiotics
b. When not to order probiotics
c. Dose
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Guideline for Ordering a Probiotic
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Appendix F
Probiotic Survey

Check one:
_______Physician
_______Nurse
How long have you been in practice?

____________

For the following statements please answer according to the
scale below: Thank you.
Strongly
Agree
1

Agree

Undecided

Disagree

2

3

4

Strongly
Disagree
5

_____Antibiotic Associated Diarrhea (AAD) is a significant
health problem.
_____AAD can cause increased mortality, length of stay and cost
of medical care for hospitalized patients.
_____There is sufficient evidence to support the routine
administration of a probiotic concurrently with an antibiotic to
reduce the occurrence and severity of AAD.
_____In most patients, probiotics are a simple, safe, cost
effective method of decreasing the occurrence and severity of
AAD.
_____I do not think probiotics are effective in reducing or
preventing AAD.
_____I believe the use of probiotics may be unsafe for many
patients.
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The following questions are designed to assess knowledge about
probiotics and their use with antibiotics. Please answer to the
best of your ability. If you do not know the answer, please
indicate that you do not know rather than leaving the question
blank. Please circle the correct answer or fill in the blank.
Thank you for completing this questionnaire.
1.

Which statements about probiotics are true?
a. Probiotics exhibit the same benefits, regardless of
strain.
b. Probiotics exhibit strain-specific differences.
c. Probiotics are not of human origin.
d. Probiotics are affected by gastric acid and bile.
e. Unable to answer

2.

The therapeutic dose of lactobacillus rhamnosus GG (LGG) is:
a.
b.
c.
d.
e.

Once a day 1010 colony forming units
TID 1010 colony forming units
BID 1010 colony forming units
QID 1010 colony forming units
Unable to answer

3. What probiotics have the most level 1 supportive evidence
(evidence derived from at least one properly designed randomized
controlled trial)?
a.
b.
c.
d.
e.

S. thermophilus and L. bulgaricus
Saccharomyces boulardii and lactobacillus GG
S. thermophilus and lactobacillus GG
lactobacillus GG and L. bulgaricus
Unable to answer

4. Have you ever prescribed or recommended a probiotic to a
patient (either from a food source or an OTC supplement)?
Yes

No

5. If you answered “no” to #4, do you have specific
reservations about probiotics?
________________________________________________________________

Probiotics

48

6. Have you known people who have used probiotics effectively
(either from a food source or supplement)?
Yes

No

7. Have you personally used probiotics either in food sources
or supplements?
Yes

No

8. What might encourage you to prescribe or recommend
probiotics?
________________________________________________________________
________________________________________________________________
9. What is the major patient risk factor for the development of
AAD?
a. Poor general health
b. Poor nutrition
c. Age
d. Alteration in intestinal flora
e.Unable to answer
10. Antibiotic use has risen ________________% from 2002 to
2006.
a. 1%
b. 7%
c. 25%
d. 40%
e.Unable to answer
11. In the last decade there has been a ______________%
increase in AAD.
a.
b.
c.
d.
e.

25%
50%
100%
500%
Unable to answer
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The highest incidence of AAD is in:
a.
b.
c.
d.
e.

The outpatient population
The intensive care unit
The pediatric population
The general medical unit
Unable to answer

13. What is the incidence of clostridium difficile acquisition
among hospitalized patients?
a. 13% in patients with hospital stays of up to two weeks
and 50% in those patient with hospital stay of up to
four weeks
b. 30% of all patients admitted to the hospital
c. 7% in patients with hospital stays of up to two weeks
and 20% in those patient with hospital stay of up to
four weeks
d. 25% in patients with hospital stays of up to two weeks
and 50% in those patient with hospital stay of up to
four weeks
e. Unable to answer
14.

All antibiotics have the potential of causing AAD.
True False

15.

Name three types of antibiotics that can reduce the number
of gut anaerobes:
1.____________________________________
2.____________________________________
3.____________________________________

Probiotics
16. Probiotics should be used with caution in patients who
have/are: (check all that apply)
_____immune compromised
_____receiving multiply antibiotics
_____short bowel syndrome
_____central venous catheter
_____elderly
_____cardiac valve disease
17. How likely are you to prescribe or recommend a probiotic
concurrently with an antibiotic?
_____Very likely
_____Somewhat likely
_____Neither likely nor unlikely
_____Somewhat unlikely
_____Unlikely
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Appendix G
Timeline
Develop
Provider
Education

Collect
Posttests

Evaluation

April, 2009

June

October, 2009

May/June, 2009

September,
2009

November, 2009

Provider
Education

Obtain
Prescribing
Frequency of
Probiotics
Pre & Post
Intervention

Present
Findings
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